Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy

Endocrinology

Volumn 149, Issue 7, 2008, Pages 3286-3293

  Samuel, Chrishan S ^a   Hewitson, Tim D ^a   Zhang, Yuan ^a   Kelly, Darren J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE; INTERSTITIAL COLLAGENASE; RELAXIN; STREPTOZOCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLE; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HYPERGLYCEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT;

ACTINS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD PRESSURE; BLOTTING, WESTERN; CARDIOMYOPATHIES; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; FIBROSIS; GELATINASES; HEMODYNAMICS; HUMANS; MALE; MATRIX METALLOPROTEINASE 13; MICE; RATS; RECOMBINANT PROTEINS; RELAXIN; RENIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 46349103257     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0250     Document Type: Article

References (44)

1. Blonde L 2007 State of diabetes care in the United States. Am J Manag Care 13(Suppl 2):S36-S40
2. Asbun J, Villarreal FJ 2006 The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47:693-700
3. Seeland U, Haeuseler C, Hinrichs R, Rosenkranz S, Pfitzner T, Scharffetter-Kochanek K, Böhm M 2002 Myocardial fibrosis in transforming growth factor-β(1) (TGF-β(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 32:295-303
4. Svensson M, Sundkvist G, Arnqvist HJ, Björk E, Blohmé G, Bolinder J, Henricsson M, Nyström L, Torffvit O, Waernbaum I, Ostman J, Eriksson JW 2003 Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26:2903-2909
5. Sherwood OD 2004 Relaxin's physiological roles and other diverse actions. Endocr Rev 25:205-234
6. Bathgate RAD, Hsueh AJ, Sherwood OD 2006 Physiology and molecular biology of the relaxin peptide family. In: Knobil E, Neill JD, eds. Physiology of reproduction, 3rd ed. San Diego: Elsevier; 679-770
7. Bani D 1997 Relaxin: a pleiotropic hormone. Gen Pharmacol 28:13-22
8. Samuel CS 2005 Relaxin: antifibrotic properties and effects in models of disease. Clin Med Res 3:241-249
9. Samuel CS, Hewitson TD 2006 Relaxin in cardiovascular and renal disease. Kidney Int 69:1498-1502
10. Becker GJ, Hewitson TD 2001 Relaxin and renal fibrosis. Kidney Int 59:1184-1185
11. Conrad KP, Novak J 2004 Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol 287:R250-R261
12. Nistri S, Bigazzi M, Bani D 2007 Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises. Cardiovasc Hematol Agents Med Chem 5:101-108
13. Dschietzig T, Bartsch C, Baumann G, Stangl K 2006 Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 112:38-56
14. Unemori EN, Amento EP 1990 Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 265:10681-10685
15. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, Amento EP 1996 Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 98:2739-2745
16. Palejwala S, Stein DE, Weiss G, Monia BP, Tortoriello D, Goldsmith LT 2001 Relaxin positively regulates matrix metalloproteinase expression in human lower uterine segment fibroblasts using a tyrosine kinase signaling pathway. Endocrinology 142:3405-3413
17. Lenhart JA, Ryan PL, Ohleth KM, Palmer SS, Bagnell CA 2001 Relaxin increases secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 during uterine and cervical growth and remodeling in the pig. Endocrinology 142:3941-3949
18. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP 2003 Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 93:1249-1257
19. Masterson R, Hewitson TD, Kelynack K, Martic M, Parry L, Bathgate R, Darby I, Becker G 2004 Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 19:544-552
20. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J, Tregear GW, Du XJ 2004 Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145:4125-4133
21. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ, Unemori EN, Iredale JP 2001 Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 49:577-583
22. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, Bathgate RA, Du XJ, Samuel CS 2005 Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46:412-418
23. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL 1998 A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 54:343-352
24. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, Krum H, Wilkinson-Berka J, Gilbert RE 2005 Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-β. Cardiovasc Res 65:694-701
25. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE, Krum H, Gilbert RE 2007 Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 76:280-291
26. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, Grove BH, Arruda JA, Dunea G 2001 Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 59:876-882
27. Garber SL, Mirochnik Y, Brecklin C, Slobodskoy L, Arruda JA, Dunea G 2003 Effect of relaxin in two models of renal mass reduction. Am J Nephrol 23:8-12
28. Kreutz R, Fernandez-Alfonso MS, Paul M, Peters J 1998 Differential development of early hypertension in heterozygous transgenic TGR(mREN2)27 rats. Clin Exp Hypertens 20:273-282
29. Boyle AJ, Kelly DJ, Zhang Y, Cox AJ, Gow RM, Way K, Itescu S, Krum H, Gilbert RE 2005 Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol 39:213-221
30. Samuel CS, Butkus A, Coghlan JP, Bateman JF 1996 The effect of relaxin on collagen metabolism in the nonpregnant rat pubic symphysis: the influence of estrogen and progesterone in regulating relaxin activity. Endocrinology 137:3884-3890
31. Gallop PM, Paz MA 1975 Posttranslational protein modifications, with special attention to collagen and elastin. Physiol Rev 55:418-487
32. Woessner Jr JF 1995 Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 248:510-528
33. Jeyabalan A, Kerchner LJ, Fisher MC, McGuane JT, Doty KD, Conrad KP 2006 Matrix metalloproteinase-2 activity, protein, mRNA, and tissue inhibitors in small arteries from pregnant and relaxin-treated nonpregnant rats. J Appl Physiol 100:1955-1963
34. Wynn TA 2007 Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117:524-529
35. Bell DS 2002 Treatment of heart failure in patients with diabetes: clinical update. Ethn Dis 12(suppl 1):S12-S18
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med [Erratum (1993) 330:152] 329:1456-1462
37. Tayebjee MH, Lip GY, MacFadyen RJ 2005 What role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus? Diabet Med 22:1628-1635
38. Catania JM, Chen G, Parrish AR 2007 Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292:F905-F911
39. Shiau MY, Tsai ST, Tsai KJ, Haung ML, Hsu YT, Chang YH 2006 Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt Sinai J Med 73:1024-1028
40. Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R 2006 Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension. J Pharmacol Exp Ther 316:8-16
41. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschöpe C 2007 Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56:641-646
42. McLennan SV, Kelly DJ, Schache M, Waltham M, Dy V, Langham RG, Yue DK, Gilbert R 2007 Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy? Kidney Int 72:481-488
43. Erikson MS, Unemori EN 2001 Relaxin clinical trials in systemic sclerosis. In: Tregear GW, Ivell R, Bathgate RA, Wade JD, eds. Relaxin 2000: Proceedings of the Third International Conference on Relaxin and Related Peptides. Amsterdam: Kluwer; 373-381
44. Seibold JR, Clements PJ, Furst DE, Mayes MD, McCloskey DA, Moreland LW, White B, Wigley FM, Rocco S, Erikson M, Hannigan JF, Sanders ME, Amento EP 1998 Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J Rheumatol 25:302-307